TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07825389: Multi-center, Phase 1b/2 Clinical Study of an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy

Sponsor: AbelZeta Inc. · Phase: PHASE1/PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 119 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$10,553,600

Rescue Site Savings

+$6,958,780

Unlock Full NCT07825389 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07825389 Rescue Dossier →